First Trust Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

First Trust Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,178	Closed	-$506K	–	2537
2023 Q2	$506K	Buy	+13,178	New	+$338K	﹤0.01%	2133
2017 Q1	–	Sell	-2,058	Closed	-$117K	–	2477
2016 Q4	$117K	Buy	+2,058	New	+$124K	﹤0.01%	2399

First Trust Advisors's KDNY Position: Q3 2023 in Review

First Trust Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 13,178 shares — an estimated $506K sold.

First Trust Advisors first reported a position in KDNY in Q4 2016 and held it in 2 quarters. The position peaked at $506K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

First Trust Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
First Trust Advisors sold 13,178 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $506K.
First Trust Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
First Trust Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $506K in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on First Trust Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.